Monopar Enterprise Value Over E B I T D A from 2010 to 2024
| MNPR Stock | USD 20.10 0.39 1.98% |
Enterprise Value Over EBITDA | First Reported 2010-12-31 | Previous Quarter 46.65 | Current Value 44.32 | Quarterly Volatility 559.8 K |
Check Monopar Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Monopar Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 23.2 K, Selling General Administrative of 3.4 B or Research Development of 5.3 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 4.19. Monopar financial statements analysis is a perfect complement when working with Monopar Therapeutics Valuation or Volatility modules.
Monopar | Enterprise Value Over E B I T D A |
Latest Monopar Therapeutics' Enterprise Value Over E B I T D A Growth Pattern
Below is the plot of the Enterprise Value Over E B I T D A of Monopar Therapeutics over the last few years. It is Monopar Therapeutics' Enterprise Value Over EBITDA historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Monopar Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Enterprise Value Over E B I T D A | 10 Years Trend |
|
Enterprise Value Over E B I T D A |
| Timeline |
Monopar Enterprise Value Over E B I T D A Regression Statistics
| Arithmetic Mean | 459,373 | |
| Coefficient Of Variation | 121.87 | |
| Mean Deviation | 528,333 | |
| Median | 46.65 | |
| Standard Deviation | 559,826 | |
| Sample Variance | 313.4B | |
| Range | 1.1M | |
| R-Value | (0.87) | |
| Mean Square Error | 83.5B | |
| R-Squared | 0.75 | |
| Significance | 0.000028 | |
| Slope | (108,588) | |
| Total Sum of Squares | 4.4T |
Monopar Enterprise Value Over E B I T D A History
About Monopar Therapeutics Financial Statements
Monopar Therapeutics shareholders use historical fundamental indicators, such as Enterprise Value Over E B I T D A, to determine how well the company is positioned to perform in the future. Although Monopar Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Monopar Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Monopar Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Enterprise Value Over EBITDA | 46.65 | 44.32 |
Pair Trading with Monopar Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Monopar Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Monopar Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Monopar Stock
| 0.86 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.82 | AGL | agilon health Buyout Trend | PairCorr |
| 0.81 | NKTX | Nkarta Inc | PairCorr |
| 0.79 | MTEM | Molecular Templates | PairCorr |
| 0.78 | ME | 23Andme Holding | PairCorr |
The ability to find closely correlated positions to Monopar Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Monopar Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Monopar Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Monopar Therapeutics to buy it.
The correlation of Monopar Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Monopar Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Monopar Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Monopar Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Monopar Stock Analysis
When running Monopar Therapeutics' price analysis, check to measure Monopar Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Monopar Therapeutics is operating at the current time. Most of Monopar Therapeutics' value examination focuses on studying past and present price action to predict the probability of Monopar Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Monopar Therapeutics' price. Additionally, you may evaluate how the addition of Monopar Therapeutics to your portfolios can decrease your overall portfolio volatility.